AbCellera (ABCL) Q4 2025 earnings review
Patent Settlement Masks Core Revenue Decline as Clinical Pivot Advances
AbCellera ended 2025 with a massive Q4 revenue surge to $44.9M, but the headline number is an illusion—60% of FY25 total revenue came from a one-time patent litigation settlement. Excluding this, core research fees continued their guided deceleration as the company actively pivots from a partnered-discovery model to a clinical-stage biotech. The operational execution of this pivot is rock-solid: lead asset ABCL635 advanced into Phase 2, and the new clinical manufacturing facility is officially open. With ~$700M in liquidity, the company has a fortress balance sheet providing a runway well beyond the critical 2026 clinical readouts, but until then, financial metrics will remain noisy and largely irrelevant.
🐂 Bull Case
AbCellera has successfully transitioned to a clinical-stage company. ABCL635 is now in Phase 2, ABCL575 is progressing through Phase 1, and two other programs (ABCL688 and ABCL386) have entered IND/CTA-enabling studies.
With ~$700M in available liquidity (cash, marketable securities, and government funding), the company ensures multi-year funding without near-term dilution risk, comfortably bridging the gap to H2 2026 clinical catalysts.
🐻 Bear Case
Legacy fee-for-service research revenue is dropping as the company shifts focus to internal programs. Q4's massive revenue beat was entirely driven by a $46.9M one-off litigation settlement, obscuring the underlying top-line contraction.
The entire valuation thesis now hinges on unproven internal assets like ABCL635, which must successfully prove target engagement without crossing the blood-brain barrier while facing entrenched small-molecule competitors.
⚖️ Verdict: ⚪
Neutral. The transition to a clinical-stage biotech is progressing flawlessly on the operational side, and liquidity is outstanding. However, core revenues are fading, and equity value depends entirely on 2026 clinical data. The Q4 'beat' is a pure one-off that doesn't change the long-term, binary thesis.
Key Themes
Core Research Revenue Decelerating
As expected, the strategic shift away from a fee-for-service model is eroding core revenues. While FY25 total revenue hit $75.1M, a massive $46.9M of that came from licensing and royalty revenue—specifically an upfront patent litigation settlement recognized in Q4. Research fees remained relatively stable YoY at $27.2M but are significantly decelerating from the $35.6M seen in FY23. This is a reversing trend for headline revenue but a clear deceleration in the core underlying business.
Internal Pipeline Maturation
The clinical pivot is moving at a stable, rapid clip. AbCellera entered 2026 with a maturing proprietary pipeline. Lead asset ABCL635 (for menopausal VMS) successfully advanced into the Phase 2 portion of its clinical trial at the end of 2025. Meanwhile, ABCL575 (OX40L for immunology) is progressing through Phase 1. The company also announced that ABCL386 for oncology has entered IND/CTA-enabling studies, joining ABCL688 (autoimmunity).
Robust Liquidity Runway
Management ended FY25 with $561M in cash, equivalents, and marketable securities, plus $135M in available non-dilutive government funding, totaling ~$700M. While total liquidity is decelerating from $840M at the end of FY24, the current burn rate implies a stable runway extending well past the critical 2026 clinical readouts, insulating the stock from near-term capital raises.
Strategic Completion of Platform Investments
AbCellera officially completed its multi-year platform investments and opened its clinical manufacturing facility in 2025. This integrated CMC capability allows the company to control Phase 1/2 clinical supply directly, potentially accelerating development timelines and protecting its pipeline from third-party CDMO manufacturing bottlenecks.
Target Engagement and Competitive Risks for ABCL635
While ABCL635 targets a massive $2B+ market for VMS, the primary scientific risk remains translating preclinical evidence of target engagement into humans. The monoclonal antibody must successfully engage NK3R in the brain without crossing the blood-brain barrier. Furthermore, the molecule faces stiff, established competition from already-approved small molecules like Astellas's VEOZAH and Bayer's elinzanetant.
Partnered Programs Stagnating
Partner-initiated program starts reached 104 cumulatively, up from 96 in 2024. However, progress through the clinic for partnered assets remains agonizingly slow. With core research revenues shrinking, the long-term downstream optionality from these 104 programs—which management points to as future royalty streams—is moving further into the future, contradicting the positive near-term narrative of pipeline growth.
Other KPIs
Accelerating. FY25 R&D expenses jumped 12% YoY from $167.3M in FY24. This reflects the expensive reality of becoming a clinical-stage biotech. Notably, $21.0M of specific investments were directed toward internal programs in 2025, highlighting the fundamental shift in capital allocation away from partner-led discovery and towards proprietary drug development.
Decelerating cash position. Net cash used in operating activities accelerated to -$131.3M in FY25 from -$108.6M in FY24. This increasing cash burn is a direct consequence of funding internal Phase 1 and Phase 2 clinical trials, combined with the structural winding down of upfront research fees from legacy partnerships.
Guidance
Stable. Management's presentation targets a topline readout for the ABCL635 Phase 1/2 clinical trial in the second half of 2026. This is the ultimate binary event for the stock and will validate (or invalidate) the company's GPCR antibody platform.
Stable. Topline Phase 1 data for the OX40L program in immunology & inflammation is also expected in H2 2026, marking another crucial de-risking event for the internal pipeline.
Key Questions
Post-Settlement Revenue Run Rate
Given the $46.9M upfront settlement payment recognized in Q4, are there any lingering milestone or royalty tails attached to this specific patent litigation, or should investors expect total revenue to immediately revert to the low single-digit millions per quarter?
ABCL386 Oncology Positioning
As ABCL386 enters IND-enabling studies for oncology, what specifically differentiates this asset in an increasingly crowded landscape, and is it derived from the T-Cell Engager platform you've previously highlighted?
Post-CapEx Cash Burn
With liquidity dropping from $840M to $700M over the year and the clinical manufacturing facility now open, how much will CapEx structurally drop in FY26, and what is your projected normalized operating burn rate as ABCL635 and ABCL575 expand into larger trials?